755 related articles for article (PubMed ID: 24309097)
1. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
[TBL] [Abstract][Full Text] [Related]
2. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
Marek GJ; Aghajanian GK
J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: novel targets for antipsychotic drugs.
Fuxe K; Borroto-Escuela DO; Tarakanov AO; Romero-Fernandez W; Ferraro L; Tanganelli S; Perez-Alea M; Di Palma M; Agnati LF
Prog Brain Res; 2014; 211():113-39. PubMed ID: 24968778
[TBL] [Abstract][Full Text] [Related]
4. Diversity and Bias through Receptor-Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization.
Fuxe K; Tarakanov A; Romero Fernandez W; Ferraro L; Tanganelli S; Filip M; Agnati LF; Garriga P; Diaz-Cabiale Z; Borroto-Escuela DO
Front Endocrinol (Lausanne); 2014; 5():71. PubMed ID: 24860548
[TBL] [Abstract][Full Text] [Related]
5. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD).
Schindler EA; Dave KD; Smolock EM; Aloyo VJ; Harvey JA
Pharmacol Biochem Behav; 2012 Mar; 101(1):69-76. PubMed ID: 22197710
[TBL] [Abstract][Full Text] [Related]
6. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT
De Gregorio D; Posa L; Ochoa-Sanchez R; McLaughlin R; Maione S; Comai S; Gobbi G
Pharmacol Res; 2016 Nov; 113(Pt A):81-91. PubMed ID: 27544651
[TBL] [Abstract][Full Text] [Related]
7. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.
Lian J; Huang XF; Pai N; Deng C
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():62-8. PubMed ID: 23994047
[TBL] [Abstract][Full Text] [Related]
8. Serotonin 5-HT
Gener T; Tauste Campo A; Alemany-González M; Nebot P; Delgado-Sallent C; Chanovas J; Puig MV
Neuropharmacology; 2019 Nov; 158():107743. PubMed ID: 31430459
[TBL] [Abstract][Full Text] [Related]
9. Serotonin 5-HT
García-Bea A; Miranda-Azpiazu P; Muguruza C; Marmolejo-Martinez-Artesero S; Diez-Alarcia R; Gabilondo AM; Callado LF; Morentin B; González-Maeso J; Meana JJ
Eur Neuropsychopharmacol; 2019 Dec; 29(12):1453-1463. PubMed ID: 31734018
[TBL] [Abstract][Full Text] [Related]
10. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
11. LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.
Halberstadt AL; Geyer MA
Psychopharmacology (Berl); 2010 Feb; 208(2):179-89. PubMed ID: 19937319
[TBL] [Abstract][Full Text] [Related]
12. Acute Cocaine Enhances Dopamine D
Borroto-Escuela DO; Narváez M; Romero-Fernández W; Pinton L; Wydra K; Filip M; Beggiato S; Tanganelli S; Ferraro L; Fuxe K
Mol Neurobiol; 2019 Oct; 56(10):7045-7055. PubMed ID: 30972626
[TBL] [Abstract][Full Text] [Related]
13. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
Marona-Lewicka D; Thisted RA; Nichols DE
Psychopharmacology (Berl); 2005 Jul; 180(3):427-35. PubMed ID: 15723230
[TBL] [Abstract][Full Text] [Related]
14. Diversity and bias through dopamine D2R heteroreceptor complexes.
Borroto-Escuela DO; Fuxe K
Curr Opin Pharmacol; 2017 Feb; 32():16-22. PubMed ID: 27838588
[TBL] [Abstract][Full Text] [Related]
15. LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex.
Arvanov VL; Liang X; Russo A; Wang RY
Eur J Neurosci; 1999 Sep; 11(9):3064-72. PubMed ID: 10510170
[TBL] [Abstract][Full Text] [Related]
16. Differential signaling signatures evoked by DOI versus lisuride stimulation of the 5-HT
Banerjee AA; Vaidya VA
Biochem Biophys Res Commun; 2020 Oct; 531(4):609-614. PubMed ID: 32814630
[TBL] [Abstract][Full Text] [Related]
17. The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.
Jalal B
Psychopharmacology (Berl); 2018 Nov; 235(11):3083-3091. PubMed ID: 30288594
[TBL] [Abstract][Full Text] [Related]
18. Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites.
Buchborn T; Schröder H; Dieterich DC; Grecksch G; Höllt V
Behav Brain Res; 2015 Mar; 281():62-8. PubMed ID: 25513973
[TBL] [Abstract][Full Text] [Related]
19. Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex.
Schindler EA; Harvey JA; Aloyo VJ
Brain Res; 2013 Jan; 1491():98-108. PubMed ID: 23123701
[TBL] [Abstract][Full Text] [Related]
20. Pimavanserin exhibits serotonin 5-HT
Muneta-Arrate I; Diez-Alarcia R; Horrillo I; Meana JJ
Eur Neuropsychopharmacol; 2020 Jul; 36():83-89. PubMed ID: 32517960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
